Navigation Links
MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting

/p>

Study Results on Receptor Interactions of Aloxi Versus Other 5-HT3 Receptor Antagonists

The results of studies characterizing the molecular ligand-receptor interactions of Aloxi and the other 5-HT3 receptor antagonists, ondansetron and granisetron, were reported. Competitive versus allosteric interactions between these agents and the 5-HT(3) receptor were examined in binding experiments using each unlabeled antagonist in competition with ((3)H)-antagonist. Concentrations of ((3)H)-antagonists were representative of the probable concentrations of each antagonist at the receptor site in vivo. Based on a plot of the concentration of unlabeled antagonist needed to observe half maximal binding (IC50) as a function of ((3)H)-antagonist concentration, Aloxi demonstrated dual action suggesting competitive and allosteric interactions with the 5-HT3 receptor. In contrast, ondansetron and granisetron exhibited strictly competitive antagonism. The Aloxi allosteric interaction with the 5-HT3 receptor indicates that it has additional inhibitory potential at the primary receptor binding site compared to the other 5-HT3 receptor antagonists studied.

Study of a Single Day Combination of Aloxi, Dexamethasone and Aprepitant in Patients Receiving Moderately Emetogenic Chemotherapy (MEC) Regimens

The results of a study evaluating the efficacy of Aloxi in combination with dexamethasone and aprepitant given only on Day 1 for the prevention of acute and delayed CINV in patients receiving MEC were presented in a poster session on Saturday, June 2, 2007. Forty-one patients (40 female, 1 male) with solid tumors received a 1-day, 3-drug regimen of intravenous Aloxi 0.25 mg, oral dexamethasone 20 mg and aprepitant 285 mg prior to their first cycle of chemotherapy. Endpoints of the study included complete response (no emesis or rescue medication), no emesis, and no significant nausea (Visual Analogue Score (VAS; 0-100) less than 25) on Day 1, during the delayed period
'"/>




Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
5. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
8. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
9. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
10. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
11. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
Post Your Comments:
(Date:3/4/2015)... 2015  Bayer HealthCare today announced that the ... the company,s Biologics License Application (BLA) for BAY ... seeking FDA approval of the investigational compound, proposed ... A in children and adults. ... to hemophilia A patients who need them," said ...
(Date:3/4/2015)...   HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... Godshall is scheduled to present at the 2015 ... on Tuesday, March 10, 2015.  The conference is being ... in Florida . A ...
(Date:3/4/2015)... INDIANAPOLIS , March 4, 2015  Students from ... look at how new medicines are discovered. Through a ... and fourth-year medical students from IU School of Medicine ... physicians working at Lilly play different and important roles ... "As a former medical educator, scientific investigator, and ...
Breaking Medicine Technology:FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 3HeartWare Presentation At The 2015 Barclays Global Healthcare Conference To Be Webcast 2Lilly and IU School of Medicine Partner on Rotation Program for Medical Students 2Lilly and IU School of Medicine Partner on Rotation Program for Medical Students 3
(Date:3/5/2015)... 05, 2015 Medical professionals suggest the ... it’s a crisis that is worsening. The demand for ... to stay on top of the physician shortage, health ... to meet face-to-face with physicians and advanced practitioners throughout ... Job Fair series. , Physician openings take an average ...
(Date:3/4/2015)... 05, 2015 The emergence of ... over the past decade. The pharmaceutical world has ... delivery in the form of liposomes and polymeric ... with more safety and efficiency. In the ... rely greatly upon the enhanced permeability and retention ...
(Date:3/4/2015)... 05, 2015 The Asia-Pacific phthalic ... of $5,632.8 million by 2019, at a CAGR ... to 2019. , Browse through the TOC of ... industry trends and segments, with the help of ... Phthalic Anhydride (PA) is a derivative of phthalic ...
(Date:3/4/2015)... March 04, 2015 Dr. Christopher Asandra, ... Medical Center today lamented the FDA’s recent decision ... (TRT). He argued that FDA’s conclusions are not ... men who suffer from testosterone deficiency. , “The FDA ... on testosterone replacement therapy,” said Dr. Asandra. “There is ...
(Date:3/4/2015)... FDA’s New Inspection Approach:, What Your Inspector ... 2015 — 1:30 p.m. – 3:00 p.m. EDT, ... hours of an inspection whether a manufacturer’s in trouble ... list, they’ll merely ask for reassurance that they know ... “bad” list, the manufacturer must get ready to convince ...
Breaking Medicine News(10 mins):Health News:Physician Shortage Crisis Worsening 2Health News:Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com 2Health News:Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com 3Health News:The Asia-Pacific Ohthalic Anhydride Market is Estimated to Reach $5,632.8 Million by 2019 - A Report by MicroMarket Monitor 2Health News:The Asia-Pacific Ohthalic Anhydride Market is Estimated to Reach $5,632.8 Million by 2019 - A Report by MicroMarket Monitor 3Health News:NuMale’s Dr. Christopher Asandra: FDA Suffering from “Premature Equivocation” on Issue of Testosterone and Risks 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4
... -- Teenagers, generally not renowned for their good eating ... they start the day with breakfast, researchers report. This ... teen is also a mom because she becomes a role ... 1,330 teen mothers in 27 states, found that those who ...
... Agarwal, MD, the chief of surgical critical care at ... medicine at Boston University School of Medicine (BUSM), has ... (NTI) to identify optimal treatment methods for acute lung ... involves seven level one trauma centers and includes one ...
... new study led by an NYU School of Medicine investigator ... International Journal of Obesity , challenges the idea that ... teenagers or what parents purchase for their children. Teens appear ... adults, however they respond at a lower rate. The conclusions ...
... By Alan Mozes HealthDay Reporter , MONDAY, ... higher risk of dying from a heart attack, regardless of ... cardiovascular disease, a new study reveals. The finding stems ... suggests that there is something about carrying around excess weight ...
... Ill. A study in the Feb. 15 issue ... found that poor sleep quality correlated with higher levels ... greater functional disability in patients with Rheumatoid Arthritis (RA). ... or behavioral interventions may have a critical impact on ...
... can increase the number of patients with heart disease referred ... them to reduce their risk of dying and improve their ... Centre. Previous studies, including one by Taylor in ... illness, such as a heart attack, can reduce the risk ...
Cached Medicine News:Health News:Calorie labeling has no effect on teenagers' or parents' food purchases 2Health News:Calorie labeling has no effect on teenagers' or parents' food purchases 3Health News:Obesity Alone Raises Risk of Fatal Heart Attack, Study Finds 2Health News:Obesity Alone Raises Risk of Fatal Heart Attack, Study Finds 3Health News:Poor sleep quality is associated with greater disability in rheumatoid arthritis patients 2Health News:Heart patients should be referred to Cardiac Rehabilitation before leaving hospital 2Health News:Heart patients should be referred to Cardiac Rehabilitation before leaving hospital 3
... The WaveScan WaveFront System is an ... error and wavefront aberrations of the human ... measurements can be used to determine regular ... cause decreased or blurry vision in the ...
... device gives you the ... and display the optical ... eye. This capability permits ... better understanding of how ...
... RELIEF® eye drops quickly remove ... & other pollutants and provide ... wind and the sun. This ... moisturizer, LIQUIFILM®, to soothe, cool ...
... LIQUIGEL® Lubricant Eye Drops combines the ... convenience of a liquid eye drop ... extra-strength CMC formula provides lubrication on ... with the PURITE® preservative, youll avoid ...
Medicine Products: